Quantumzyme Corp. (OTCQB: QTZM), a biotechnology company specializing in enzyme engineering and green chemistry, announced details regarding the World Intellectual Property Organization (WIPO) publication of its international patent application titled "Modified Polypeptides for Enzymatic Synthesis of Ibuprofen" (Publication No. WO 2025/093935 A1). Although published in May 2025, the company is highlighting it now to underscore its commitment to innovation in sustainable pharmaceutical manufacturing.
This announcement follows the earlier publication of its U.S. Patent Application (U.S. Patent Application Publication No. US 2025/0146029 A1) covering related enzymatic processes. Together, these filings establish broad protection for Quantumzyme's proprietary enzyme engineering platform in both the United States and international markets, strengthening the company’s intellectual property portfolio and representing a major step toward commercializing its enzymatic process for sustainable ibuprofen manufacture.
The patented ibuprofen synthesis builds on Quantumzyme’s proprietary QZyme Workbench™ platform, which integrates quantum mechanics, molecular modeling, and AI-driven optimization to design next-generation biocatalysts. This technology underlies multiple enzyme systems the company is developing for sustainable, high-efficiency production of active pharmaceutical ingredients (APIs) and specialty chemicals.
“The publication of our patents both in the USA and internationally mark an important milestone for Quantumzyme,” stated Naveen Kulkarni, CEO of Quantumzyme Corp. “It validates the strength of our enzyme engineering technology and enhances our position for global partnerships focused on greener, more efficient pharmaceutical manufacturing. It also allows us to advance into the optimization and pilot-testing phase, and engaging with potential partners interested in sustainable and scalable API production.”
Quantumzyme intends to continue laboratory optimization and scale-up validation of the enzymatic ibuprofen synthesis process, pursue discussions with global pharmaceutical and contract manufacturing organizations (CMOs) regarding licensing or joint-development frameworks, and file additional patent applications covering related enzymatic transformations and process improvements.
For more information, visit www.quantumzymecorp.com and the Company’s profile at www.otcmarkets.com/stock/QTZM.
